Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Lung Cancer

  Free Subscription


22.09.2025

1 AJR Am J Roentgenol
2 Ann Surg Oncol
2 BMC Cancer
1 Cancer Res
2 Clin Lung Cancer
2 Eur J Cancer
2 Eur Respir J
1 Genes Chromosomes Cancer
1 Int J Cancer
1 J Cancer Res Clin Oncol
2 J Comput Assist Tomogr
3 JAMA Oncol
1 Lancet Oncol
2 Lung Cancer
1 Lung Cancer (Auckl)
1 Oncogene
3 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. WU YJ, Wu FZ
    When Artificial Intelligence Steers the Boat: Utilization Scenarios for Low-Dose CT Lung Cancer Screening.
    AJR Am J Roentgenol. 2025 Sep 17. doi: 10.2214/AJR.25.33722.
    PubMed        


    Ann Surg Oncol

  2. LIU J, Ma H, Li D, Li Y, et al
    ASO Visual Abstract: Early Post-Discharge Pain Trajectories After Thoracoscopic Sublobar Resection for Stage IA Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2025 Sep 17. doi: 10.1245/s10434-025-18369.
    PubMed        

  3. SONODA D, Kondo Y, Maruyama R, Mitsuhashi S, et al
    ASO Visual Abstract: Characteristics of Patients with Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Q787Q Mutation.
    Ann Surg Oncol. 2025 Sep 16. doi: 10.1245/s10434-025-18366.
    PubMed        


    BMC Cancer

  4. ABDEL-HAFEZ SH, Alexeree SMI
    Evaluating the anticancer properties of VAF: a novel folate-alpha-tocopherol conjugate against lung cancer cells.
    BMC Cancer. 2025;25:1423.
    PubMed         Abstract available

  5. ZENG Y, Wang Q, Qiao D, Dai B, et al
    METTL16-dependent GPX4 m(6)A modification links ferroptosis to NSCLC TKIs resistance.
    BMC Cancer. 2025;25:1335.
    PubMed         Abstract available


    Cancer Res

  6. KNOLL N, Masser S, Bordas B, Ebright RY, et al
    CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer.
    Cancer Res. 2025;85:3518-3539.
    PubMed         Abstract available


    Clin Lung Cancer

  7. BRONSTEIN A, Curcio H, Monnet I, Ricordel C, et al
    Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis.
    Clin Lung Cancer. 2025 Aug 21:S1525-7304(25)00198.
    PubMed         Abstract available

  8. DESAI A, McNeeley E, Alhushki S, Haught M, et al
    DISCERN: A Randomized Pilot Study Comparing Dual Versus Single Immune Checkpoint Blockade Plus Chemotherapy in PD-L1 Negative Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Aug 26:S1525-7304(25)00220.
    PubMed         Abstract available


    Eur J Cancer

  9. NAGASHIMA H, Fukuhara T, Utsumi Y, Suzuki A, et al
    A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study.
    Eur J Cancer. 2025;229:115693.
    PubMed         Abstract available

  10. SHIRAISHI Y, Shimose T, Tachihara M, Tsuchiya-Kawano Y, et al
    Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).
    Eur J Cancer. 2025;229:115779.
    PubMed         Abstract available


    Eur Respir J

  11. IMAI R, Fukui S, Inoue K
    Pirfenidone and lung cancer in idiopathic pulmonary fibrosis: mind the index date, detection bias and competing risks.
    Eur Respir J. 2025;66:2500453.
    PubMed        

  12. YOON HY, Song JW
    Reply to: Pirfenidone and lung cancer in idiopathic pulmonary fibrosis: mind the index date, detection bias and competing risks.
    Eur Respir J. 2025;66:2501350.
    PubMed        


    Genes Chromosomes Cancer

  13. AGAIMY A, Dermawan JK, Rios E, Meidenbauer N, et al
    NFATC2::NUTM2A/B Fusions Characterize a Novel Indolent Myoepithelial-Like Neoplasm of the Lungs and Salivary Glands.
    Genes Chromosomes Cancer. 2025;64:e70083.
    PubMed         Abstract available


    Int J Cancer

  14. ZHAO Z, Rong H, Li M, Xu Y, et al
    Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited-stage small-cell lung cancer: A retrospective, multi-center, real-world study.
    Int J Cancer. 2025 Sep 13. doi: 10.1002/ijc.70153.
    PubMed         Abstract available


    J Cancer Res Clin Oncol

  15. CHEN X, Kong R, Qi Y, Li L, et al
    MiR-26b-5p mediates radioresistance and immunosuppression via targeting PRKCD in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2025;151:262.
    PubMed         Abstract available


    J Comput Assist Tomogr

  16. CHEN Y, Liu J, Ji J, Zhao Y, et al
    Computed Tomography Combined With Real-time Ultrasound-guided Percutaneous Needle Biopsy of Peripleural Lung Nodules.
    J Comput Assist Tomogr. 2025;49:751-758.
    PubMed         Abstract available

  17. MURAT A, Zeynep B, Ramazan G, Zeynep Nilufer T, et al
    Association Between Sarcopenia Measurement in Pectoral Region and Immediate Complications Following Percutaneous Transthoracic Lung Biopsy.
    J Comput Assist Tomogr. 2025;49:769-776.
    PubMed         Abstract available


    JAMA Oncol

  18. DI Y, Song Z, Meng L
    Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 Sep 18. doi: 10.1001/jamaoncol.2025.3491.
    PubMed        

  19. BERTOLACCINI L, de Marinis F, Spaggiari L
    Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 Sep 18. doi: 10.1001/jamaoncol.2025.3494.
    PubMed        

  20. GARBO E, Ricciuti B, Cappuzzo F
    Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2025 Sep 18. doi: 10.1001/jamaoncol.2025.3497.
    PubMed        


    Lancet Oncol

  21. COLLINGRIDGE D
    2025 World Conference on Lung Cancer.
    Lancet Oncol. 2025 Sep 11:S1470-2045(25)00548.
    PubMed        


    Lung Cancer

  22. TU HY, Chen C, Chen C, Cheng C, et al
    Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancer.
    Lung Cancer. 2025;208:108716.
    PubMed         Abstract available

  23. SUN F, Banwait MK, Singhal S, Herrmann A, et al
    Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.
    Lung Cancer. 2025;208:108747.
    PubMed         Abstract available


    Lung Cancer (Auckl)

  24. WANG J, Biglow L, Baumgart M
    Emerging Targets in Non-Small Cell Lung Cancer.
    Lung Cancer (Auckl). 2025;16:115-124.
    PubMed         Abstract available


    Oncogene

  25. PENG J, Zhang Q, Rao X, Allison DB, et al
    PLK1-mediated PDHA1 phosphorylation drives metabolic reprogramming in lung cancer.
    Oncogene. 2025 Sep 16. doi: 10.1038/s41388-025-03571.
    PubMed         Abstract available


    PLoS One

  26. WANG Y, Mustaza SM, Ab-Rahman MS, Mokri SS, et al
    HEE-SegGAN: A holistically-nested edge enhanced GAN for pulmonary nodule segmentation.
    PLoS One. 2025;20:e0328629.
    PubMed         Abstract available

  27. XIAO Z, Long Q, Liao J, Huang F, et al
    The role of SLC2A1 in lung adenocarcinoma: From tumorigenesis to patient survival.
    PLoS One. 2025;20:e0324043.
    PubMed         Abstract available

  28. ZHANG Q, Fu C, Liu S, Leng Y, et al
    Construction and validation of a prognostic model based on mitochondria-associated endoplasmic reticulum membranes gene signature in LUAD patients.
    PLoS One. 2025;20:e0330722.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.